Compare CMRE & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMRE | MESO |
|---|---|---|
| Founded | 1974 | 2004 |
| Country | Monaco | Australia |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2010 | 2005 |
| Metric | CMRE | MESO |
|---|---|---|
| Price | $14.05 | $12.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $20.00 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 347.2K | 248.0K |
| Earning Date | 11-03-2026 | 08-26-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $59.17 |
| Revenue Next Year | N/A | $59.00 |
| P/E Ratio | $5.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.45 | $11.89 |
| 52 Week High | $18.06 | $21.50 |
| Indicator | CMRE | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 34.52 |
| Support Level | $13.86 | N/A |
| Resistance Level | $15.76 | $16.06 |
| Average True Range (ATR) | 0.45 | 0.42 |
| MACD | -0.10 | -0.10 |
| Stochastic Oscillator | 25.12 | 15.12 |
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and others. The company provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.